NCT06198413Active, not recruitingPhase 1
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Source: ClinicalTrials.gov · Last updated 1 Jul 2025
Brief summary (registry, in English)
The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 25 Dec 2023
- Start date
- 27 Feb 2023
- Primary completion date
- 26 Dec 2024
- Lead sponsor
- Innostellar Biotherapeutics Co.,Ltd
- Diseases
- Macular degeneration
- NCT number
- NCT06198413
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 12
- From 27 Feb 2023 to the primary completion date, 26 Dec 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- CNV or macular edema in the study eye secondary to diseases other than nAMD
- Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement
- Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months
- Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg
Lab values
- Uncontrolled diabetes defined as HbA1c \>7.5%
Who the study is looking for
- Willing to sign the informed consent, and willing to attend follow-up visits.
- Age ≥ 50
- Diagnosis of active CNV secondary to neovascular AMD
- BCVA ETDRS letters between 5 and 63
- Subjects must have received a minimum of 2 injections within 6 months prior to screening
- Demonstrated a meaningful response to anti-VEGF therapy
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang University Eye Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| Anhui Provincial Hospital Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Shanghai General Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.